Risk factors for respiratory syncytial virus hospitalisation in children with heart disease

Kristensen, Kim; Stensballe, Lone Graff; Bjerre, Jesper Vandborg; Roth, Ditte; Fisker, Niels; Kongstad, Thomas; Svendsen, Anne Louise; Nielsen, Bent Windelborg

doi:10.1136/adc.2008.143057

Cited by 53 publications

(57 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Down syndrome (DS) is an independent risk factor for respiratory illness and severe respiratory syncytial virus (RSV)-related infection and hospitalization in children. [1][2][3][4][5][6][7][8] The combined attributes of a compromised innate and adaptive immune system in early infancy [9][10][11][12][13] with anatomic [14][15][16] and physiologic aberrations such as gastroesophageal reflux disease, 17 obstructive sleep apnea, 18 and hemodynamically significant heart disease 4,19 all lead to significant morbidity and mortality in DS during the first 2 years of life. [20][21][22] Palivizumab, a humanized monoclonal antibody, has been proven safe and efficacious against RSV in randomized, placebo-controlled studies involving preterm infants #35 weeks' gestational age during their first RSV season and children aged ,2 years with severe chronic lung disease (CLD) and hemodynamically significant cardiac disease.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4][5][6] Across 4 reported studies, [1][2][3]5 which have cumulatively evaluated 1646 children with DS aged ,2 years, the risk estimate for RSV hospitalizations ranged from 9.9% to a Adjusted for hemodynamically significant CHD, insignificant CHD, gestational age, and birth weight. Ratios .1 indicate higher risk in the untreated group.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study

Lanctôt

Bont

et al. 2014

Pediatrics

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVES: Children with Down syndrome (DS) are at significant risk for respiratory syncytial virus (RSV) infection and related hospitalization. We compared hospitalization rates due to respiratory tract infection in children with DS aged <2 years who prospectively received palivizumab during the RSV season with a previously published, similar untreated DS birth cohort. METHODS: A total of 532 children with DS who prospectively received palivizumab were assembled from the prospective Canadian RSV Evaluation Study of Palivizumab registry between 2005 and 2012. The untreated group included 233 children with DS derived from a nationwide Dutch birth cohort from 2003 to 2005. Events during the RSV seasons were counted. Poisson regression analysis was performed to compare incidence rate ratios (95% confidence intervals [CIs]) between groups while controlling for observation length and known risk factors for severe RSV infection. RESULTS: In total, 31 (23 untreated, 8 treated) RSV-related hospitalizations were documented. The adjusted risk of RSV-related hospitalizations was higher in untreated subjects than in palivizumab recipients (incidence rate ratio 3.63; 95% CI, 1.52–8.67). The adjusted risk of hospitalization for all respiratory tract infection (147 events; 73 untreated, 74 treated) was similar (incidence rate ratio untreated versus palivizumab 1.11; 95% CI, 0.80–1.55). CONCLUSIONS: These results suggest that palivizumab is associated with a 3.6-fold reduction in the incidence rate ratio for RSV-related hospitalization in children with DS during the first 2 years of life. A randomized trial is needed to determine the efficacy of RSV immunoprophylaxis in this specific high-risk patient population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study

Lanctôt

Bont

et al. 2014

Pediatrics

View full text Add to dashboard Cite

show abstract

“…Underlying disease, especially chronic lung disease of prematurity and haemodynamically significant congenital heart disease, is a significant predictor of prolonged hospitalisation, frequency of ICU admission and death in children hospitalised for RSV [107,109]. Conditions such as other symptomatic chronic pulmonary disorders, trisomy 21 and neuromuscular disease also increase the risk for severe disease [110][111][112]. Furthermore, a role for genetic predisposition in severe RSV disease is supported by identical twin studies [91] and observed increases in susceptibility of the male gender and specific ethnic or racial groups such as Native American and Canadian Inuit populations [108].…”

Section: Risk Factors For Severe Diseasementioning

confidence: 99%

The distinguishing features of human metapneumovirus and respiratory syncytial virus

Papenburg

Boivin

2010

Reviews in Medical Virology

View full text Add to dashboard Cite

Acute respiratory tract infections (RTIs) are a leading cause of morbidity and mortality worldwide. Human Metapneumovirus (hMPV) is a member of the Metapneumovirus genus within the Pneumovirinae subfamily of the Paramyxoviridae family. Though hMPV was only discovered in 2001, a large body of work has already shown that it is the aetiologic agent of a substantial proportion of upper and lower RTIs across all age groups in both healthy and immunocompromised hosts throughout the world. RSV, also a pneumovirus, is the human pathogen most closely related to hMPV. RSV is the leading cause of pneumonia and bronchiolitis in infants and young children, but can also cause respiratory tract disease in all age groups. In this paper, we will review the salient features of the virology, epidemiology, pathogenesis, host immune responses, clinical manifestations and diagnostic modalities of hMPV, using RSV as a comparison. In addition, we will show how immunoprophylactic and therapeutic strategies studied and used in clinical practice for RSV-some with great success, and others tragic failure-have led to promising areas of research for the prevention and treatment of the significant burden of disease caused by hMPV.

show abstract

“…They are also more prone to respiratory tract infections (RTIs) that commonly manifest in the lower airways, a major cause of hospitalization (5,6). Several factors contribute to increased risk of RTI in children with DS such as neurological impairment (7), abnormal anatomy of the upper airways (8), structural pulmonary abnormalities (9), and congenital heart defects (10). In addition, alterations in the immune system are an important cause of RTIs in DS children (11,12).…”

mentioning

confidence: 99%

“…These lower RTIs in DS children are most often caused by viral pathogens, such as respiratory syncytial virus. This can lead to severe respiratory syncytial virus bronchiolitis, a frequent cause of hospitalization in DS children (10,(26)(27)(28). Also, an increased risk of hospitalization, endotracheal intubation, and death due to influenza A virus infection was reported in DS (29).…”

mentioning

confidence: 99%

Increased production of interleukin-10 in children with Down syndrome upon ex vivo stimulation with Streptococcus pneumoniae

et al. 2013

View full text Add to dashboard Cite

Risk factors for respiratory syncytial virus hospitalisation in children with heart disease

Abstract: In children with heart disease risk factors for RSV admission are Down syndrome, cardiomyopathy and haemodynamically significant heart disease. Young age and cardiac decompensation are associated with a more severe course of RSV disease.

Cited by 53 publications

References 36 publications

Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study

Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study

The distinguishing features of human metapneumovirus and respiratory syncytial virus

Increased production of interleukin-10 in children with Down syndrome upon ex vivo stimulation with Streptococcus pneumoniae

Contact Info

Product

Resources

About